Insights
Insights From Our Experts
Articles
European Pricing Platform: The State of International Reference Pricing
Worldwide, pricing policy is always in flux. In this webinar, EVERSANA’s General Manager of Global Pricing and Access, Alan Crowther, examines global trends impacting the International Reference Pricing (IRP) landscape and discusses the possible effects these…
EVERSANA, Patient Experience Project featured in MM&M July Issue
Each year, Medical Marketing & Media compiles a list of the top 100 medical marketing agencies in North America. As MM&M Editor Stephen Madden shares at the opening of the July issue, “A typical issue of…
Breaking Down the U.S. Payer Segment
Market Access Macrotrends provides insight for you to stay on top of market access trends, anticipate how the healthcare landscape is evolving, and provide strategic guidance for your organization. Market Access Macrotrends answers your questions about changes in…
Streamline Chargeback and Channel Operations
Robert Blank, Managing Consultant at EVERSANA, moderated a panel with industry experts from Sanofi, Zydus, and UCB at CBI’s 15th Annual Commercial Contract and Chargeback Excellence. The topic: “Process Improvement in Contract Administration and Management —…
Membership Management Challenges and Best Practices
In the pharmaceutical industry, access to pricing is primarily driven by membership.Institutions like hospitals, clinics, and pharmacies sign up as members of a Group Purchasing Organization (GPO) to be eligible to purchase products at a discounted…
Pharmaceutical Contracting from Volume to Value
Driven by skyrocketing costs, market forces are hastening the shift in the healthcare industry from volume based care (fee for service) to a value based reimbursement structure (fee for value). While the inertia of entrenched policies,…
Medicaid Drug Classification: Civil Monetary Penalties
On April 18, 2019, the “Medicaid Services Investment and Accountability Act of 2019” was signed into law, bringing with it a significant change to the oversight and management of the Medicaid Drug Rebate Program (MDRP). Effective…
Gene Therapy for Rare Disorders
With only three approved products in the marketplace, how do we build a regenerative medicine ecosystem that delivers more value to patient’s faster?
Setting a Patient Engagement Framework and Proving Value
Is your culture patient-centric? It needs to be because today’s patients are motivated information seekers – empowered decision-makers with respect to their treatment. Their voice is key to your success.
Insights from AMCP 2019
EVERSANA attended (and sponsored) The Academy of Managed Care Pharmacy (AMCP) Managed Care & Specialty Pharmacy Annual Meeting. If you missed the conference, here are a few key takeaways from our colleagues who attended: 1) Federal and…